SLC5A2 and type 2 diabetes mellitus: EMPACT‐MI was the first SGLT2 inhibitor trial in acute MI to enrol those without T2DM as well as being the only post‐MI SGLT2 inhibitor trial to investigate effects on clinical outcomes.